PROPOSED REGULATION OF THE
STATE BOARD OF PHARMACY

LCB File No. R013-17

Workshop June 1st, 2017

Explanation – Language in blue italics is new; language in red text [omitted material] is language to be omitted, and language in green text indicates prior Board-approved amendments that are in the process of being codified.

AUTHORITY: §1, NRS 639.070

A REGULATION relating to a change in controlled substance schedule for Chorionic gonadotropin (HCG) in animal use.

NAC 453.530 Schedule III. (NRS 453.146, 453.2182, 639.070)

1. Schedule III consists of the drugs and other substances listed in this section, by whatever official, common, usual, chemical or trade name designated.

2. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers and salts of such isomers, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation, is hereby enumerated on schedule III, including:
   (a) Those compounds, mixtures or preparations in dosage unit form containing any substance listed in schedule II which has a stimulant effect on the central nervous system, which compounds, mixtures or preparations were listed on August 25, 1971, as excepted compounds under the regulations of the Drug Enforcement Administration of the United States Department of Justice, and any other drug of the same quantitative composition as a drug shown on the list or which is the same except that it contains a lesser quantity of controlled substances;
      (b) Benzphetamine;
      (c) Chlorphentermine;
      (d) Clortermine; or
      (e) Phendimetrazine.

☐ For the purposes of this subsection, “isomer” includes the optical, position or geometric isomer.

3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system is hereby enumerated on schedule III:
   (a) Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof;
      (b) Chlorhexadol;
      (c) Embutramide;
      (d) Lysergic acid;
(e) Lysergic acid amide;
(f) Methyprylon;
(g) Sulfondiethylmethane;
(h) Sulfonethylmethane;
(i) Sulfonmethane;
(j) Any compound, mixture or preparation containing amobarbital, secobarbital, pentobarbital
or any salt thereof and one or more other active medicinal ingredients, which are not listed in any
schedule;
(k) Any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or any
salt of any of these drugs approved by the Food and Drug Administration of the United States
Department of Health and Human Services for marketing only as a suppository; or
(l) Tiletamine and zolazepam or any salt thereof. (Some trade or other names for a tiletamine-
zolazepam combination product: Telazol. Some trade or other names for tiletamine: 2-
(ethy lamino)-2-(2-thienyl)-cyclohexanone. Some trade or other names for zolazepam: 4-(2-
fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e][1,4]-diazepin-7(1H)-one,
flupyrazapon).

4. Nalorphine is hereby enumerated on schedule III.

5. Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture or preparation containing any of the following narcotic drugs or their salts,
calculated as the free anhydrous base or alkaloid, in quantities is hereby enumerated on schedule
III:
   (a) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per
dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
   (b) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per
dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
   (c) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90
milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
therapeutic amounts;
   (d) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15
milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized
therapeutic amounts;
   (e) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more
than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in
recognized therapeutic amounts; or
   (f) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one
or more active, nonnarcotic ingredients in recognized therapeutic amounts.

6. Unless listed in another schedule, any material, compound, mixture or preparation which
contains any quantity of:
   (a) N-methylephedrine, its optical isomers, salts and salts of optical isomers;
   (b) Hydriodic acid; or
   (c) Hydrogen iodide gas,

are, as immediate precursors, controlled, the control of which is necessary to prevent, curtail
or limit the manufacture of the controlled substances methamphetamine and N, N-
dimethylamphetamine.

7. Except as otherwise provided in subsections 8 and 9, or specifically excepted or listed in
another schedule, any material, compound, mixture or preparation containing any quantity of
anabolic steroids, including their salts, isomers, esters and salts of isomers, whenever the existence of such salts of isomers is possible within the specific chemical designation, is hereby enumerated on schedule III:

(a) Androisoxazole;
(b) Androstenediol;
(c) Bolandiol;
(d) Bolasterone;
(e) Boldenone;
(f) Chlormethandienone;
(g) Clostebol;
(h) Chorionic gonadotropin (HCG);
(i) Dehydrochlormethyltestosterone;
(j) Dihydromesterone;
(k) Drostanolone;
(l) Ethylestrenol;
(m) Fluoxymesterone;
(n) Formebolone;
(o) Formyldienolone;
(p) 4-Hydroxy-19-nortestosterone;
(q) Mesterolone;
(r) Methandrenone;
(s) Methandiol;
(t) Methandrostenolone;
(u) Methenolone;
(v) 17-Methyltestosterone;
(w) Methyltrienolone;
(x) Mibolerone;
(y) Nandrolone;
(z) Norbolethone;
(aa) Norethandrolone;
(bb) Normethandrolone;
(cc) Oxandrolone;
(dd) Oxymesterone;
(ee) Oxymetholone;
(ff) Quinbolone;
(gg) Stanolone;
(hh) Stanozolol;
(ii) Stenbolone;
(jj) Testolactone;
(kk) Testosterone; or
(ll) Trenbolone.

8. Any anabolic steroid or chorionic gonadotropin (HCG) described in subsection 7 which is used solely for implantation or injection in cattle or any other nonhuman species and is approved by the Food and Drug Administration for that use is not a controlled substance.

9. The following classifications are not controlled substances for the purposes of this section:
(a) Oral combinations containing therapeutic doses of estrogen and androgen;
(b) Parenteral preparations containing therapeutic doses of estrogen and androgen;
(c) Topical preparations containing androgens or combinations of androgen and estrogen; and
(d) Vaginal preparations.

10. Ketamine, including its salts, isomers and salts of isomers, is hereby enumerated on schedule III.

11. Synthetic Dronabinol in sesame oil encapsulated in a soft gelatin capsule in a drug product approved by the Food and Drug Administration (some trade or other names: (6aR-trans)-6a,7,8,10a-tetrahydro-6; 6,9-trimethyl-3-pentyl-6H-dibenzo [b,d]pyran-1-ol; (-)-delta-9-(trans)-tetrahydrocannabinol; Marinol) is hereby enumerated on schedule III.

12. Gamma-hydroxybutyrate prepared by a registered pharmaceutical manufacturer of the Food and Drug Administration which is properly labeled, including lot numbers, and is available for medicinal purposes through a distribution system approved by the Food and Drug Administration is hereby enumerated on schedule III.

13. Human growth hormone (HGH) is hereby enumerated on schedule III.

14. Any material, compound, mixture or preparation containing buprenorphine, including its salts, is hereby enumerated on schedule III.

(Added to NAC by Bd. of Pharmacy, eff. 6-25-82; A 10-26-83; 7-2-84; 8-10-89; 2-6-90; 9-11-91; 10-1-93; 1-10-94; 7-17-96; 11-14-97; R153-99, 3-1-2000; R003-01, 11-1-2001; R163-01, 12-17-2001; R141-03, 4-8-2004; R041-07& R047-07, 12-4-2007; R181-07, 4-17-2008; R218-08, 10-27-2009; R123-09, 1-28-2010; R016-14, 10-24-2014; R137-14, 12-22-2014)